The Solute Carrier Family 22 Member 12 pipeline drugs market research report outlays comprehensive information on the Solute Carrier Family 22 Member 12 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Solute Carrier Family 22 Member 12 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Musculoskeletal Disorders, Metabolic Disorders, and Genito Urinary System which include the indications Gouty Arthritis (Gout), Hyperuricemia, and Chronic Kidney Disease (Chronic Renal Failure). It also reviews key players involved in Solute Carrier Family 22 Member 12 targeted therapeutics development with respective active and dormant or discontinued products.
The Solute Carrier Family 22 Member 12 pipeline targets constitutes close to 17 molecules. Out of which, approximately 17 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, and Preclinical stages are 1, 6, 5, 3, and 1 respectively.
Solute Carrier Family 22 Member 12 overview
Solute carrier family 22 member 12 (SLC22A12) is a protein that regulates urate levels in the blood. It’s also known as URAT1. This protein is found in the kidneys. SLC22A12 is a member of the organic anion transporter (OAT) family. It acts as a urate transporter, which is required for efficient urate re-absorption in the kidney. It also mediates saturable urate uptake by facilitating the exchange of urate.
For a complete picture of Solute Carrier Family 22 Member 12’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
